The effects of a CCR3 inhibitor, AXP1275, on allergen-induced airway responses in adults with mild-to-moderate atopic asthma.
Gail M GauvreauJ M FitzGeraldL P BouletR M WatsonL HuiH VillineuveT X ScimeA R SchlatmanC ObminskiJ KumS BoehmeT W LyK B BaconP M O'ByrnePublished in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2018)
AXP1275 50 mg administered daily was safe and well tolerated, and there was no difference in the type, severity or frequency of treatment-emergent adverse events in subjects while receiving AXP1275 compared to placebo. AXP1275 increased the methacholine PC20 ; however, the low and variable exposure to APX1275 over a short treatment period may have contributed to poor efficacy on other outcomes.